536-71-0

Basic information

• Product Name: Diminazene
• Synonyms: diminazene;4,4'-(1-triazene-1,3-diyl)bisbenzenecarboximidamide;1,3-bis(4-amidinophenyl)triazene;4,4'-(1,3-Triazenediyl)bis(benzamidine);4,4'-(Azoimino)bis(benzamidine);4,4'-(Diazoamino)dibenzamidine;4-[(4-Amidinophenylazo)amino]benzamidine;4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide
• CAS NO: 536-71-0
• Molecular Formula: C₁₄H₁₅N₇
• Molecular Weight: 281.3158
• EINECS: 208-644-6
• Product Categories: Pesticide intermediates
• Mol File: 536-71-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 463.3 °C at 760 mmHg
• Flash Point: 234 °C
• Appearance: /
• Density: 1.39 g/cm³
• Vapor Pressure: 9.21E-09mmHg at 25°C
• Refractive Index: 1.707
• PKA: 12.11±0.50(Predicted)
• CAS DataBase Reference: Diminazene(CAS DataBase Reference)
• NIST Chemistry Reference: Diminazene(536-71-0)
• EPA Substance Registry System: Diminazene(536-71-0)

Safety Data

• Hazardous Substances Data: 536-71-0(Hazardous Substances Data)

Usage

Definition

ChEBI: A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.

InChI:InChI=1/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)

Synthetic route

diminazene (536-71-0) → 4,4'-dicarbamoyldiazoaminobenzene

Conditions	Yield
With sodium carbonate

Upstream product

• 3858-83-1 p-aminobenzamidine 
• 1093268-26-8 diminazene monoamidoxime 
• 145855-63-6 diminazene diamidoxime 

Downstream Products

• 90738-25-3 Rh₂(O₂CCH₃)3(bis(4,4'-(1-triazene-1,3-diyl)dibenzamidine))dirhodium(II) 
• 90751-75-0 Rh₂(O₂C(CH₂)2CH₃)3(bis(4,4'-(1-triazene-1,3-diyl)dibenzamidine))dirhodium(II) 

Relevant articles and documents

The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs

The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b 5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.